Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids
Launched by MAYO CLINIC · Mar 26, 2021
Trial Information
Current as of May 14, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years of age.
- • Have an ECOG Performance Status of ≤ 2.
- • No evidence of distant metastasis on imaging.
- • Histologic or cytologic proven adenocarcinoma of the pancreas.
- • Providing informed consent prior to enrollment in the trial.
- Exclusion Criteria:
- • Failure to obtain additional core needle biopsies for generating PDTs.
- • Females who are pregnant or plan to become pregnant.
About Mayo Clinic
Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Panagiotis Anastasiadis, PhD
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials